Stammdaten
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Unternehmen & Branche
| Name | FENNEC PHARMACEUTICALS INC. |
|---|---|
| Ticker | FENC |
| CIK | 0001211583 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 181,3 Mio. USD |
| Beta | 0,93 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 44,642,000 | -9,741,000 | -0.34 | 70,551,000 | 35,472,000 |
| 2025-09-30 | 10-Q | 12,462,000 | -638,000 | -0.02 | 49,261,000 | -4,492,000 |
| 2025-06-30 | 10-Q | 9,652,000 | -3,152,000 | -0.11 | 44,876,000 | -7,463,000 |
| 2025-03-31 | 10-Q | 8,751,000 | -1,165,000 | -0.04 | 46,403,000 | -5,880,000 |
| 2024-12-31 | 10-K | 47,538,000 | -436,000 | -0.02 | 44,946,000 | -5,872,000 |
| 2024-09-30 | 10-Q | 6,974,000 | -5,735,000 | -0.21 | 58,921,000 | -5,171,000 |
| 2024-06-30 | 10-Q | 7,262,000 | -5,553,000 | -0.20 | 63,161,000 | -1,357,000 |
| 2024-03-31 | 10-Q | 25,377,000 | 12,837,000 | 0.41 | 69,193,000 | 3,014,000 |
| 2023-12-31 | 10-K | 21,252,000 | -16,045,000 | -0.60 | 26,864,000 | -11,622,000 |
| 2023-09-30 | 10-Q | 6,515,000 | -1,867,000 | -0.07 | 19,028,000 | -10,531,000 |
| 2023-09-30 | 10-K | 6,296,000 | 917,000 | -0.03 | 19,978,000 | 9,581,000 |
| 2023-06-30 | 10-Q | 3,325,000 | -5,444,000 | -0.21 | 19,437,000 | -9,727,000 |
| 2023-03-31 | 10-Q | 1,677,000 | -6,052,000 | -0.23 | 21,821,000 | -7,339,000 |
| 2022-12-31 | 10-K | 1,535,000 | -23,714,000 | -0.90 | 26,939,000 | -2,569,000 |
| 2022-09-30 | 10-Q | -8,089,000 | -0.31 | 30,417,000 | 2,802,000 | |
| 2022-06-30 | 10-Q | -5,072,000 | -0.19 | 15,568,000 | 8,541,000 | |
| 2022-03-31 | 10-Q | -3,696,000 | -0.14 | 19,149,000 | 12,524,000 | |
| 2021-12-31 | 10-K | -17,346,000 | -0.67 | 22,414,000 | 15,772,000 | |
| 2021-09-30 | 10-Q | -4,185,000 | -0.16 | 26,014,000 | 19,013,000 | |
| 2021-06-30 | 10-Q | -4,001,000 | -0.15 | 28,115,000 | 22,281,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Raykov Rosty | Director | Open Market Sale | -10,079 | 8.36 | -84,260.44 | -16,9% | |
| 2026-02-02 | Raykov Rosty | Director | Open Market Sale | -10,349 | 7.76 | -80,308.24 | -16,1% | |
| 2026-01-02 | Raykov Rosty | Director | Open Market Sale | -10,312 | 7.60 | -78,371.20 | -15,7% | |
| 2025-12-24 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -1,000,000 | 7.50 | -7,500,000.00 | -1502,6% | |
| 2025-12-05 | Raykov Rosty | Director | Open Market Sale | -10,000 | 7.54 | -75,400.00 | -15,1% | |
| 2025-11-18 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -19,341 | 8.79 | -170,048.01 | -34,1% | |
| 2025-11-17 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -85,918 | 8.79 | -755,193.44 | -151,3% | |
| 2025-11-14 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -160,100 | 8.00 | -1,280,431.77 | -256,5% | |
| 2025-11-05 | Raykov Rosty | Director | Open Market Sale | -10,000 | 8.10 | -81,000.00 | -16,2% | |
| 2025-10-10 | RALLIS CHRIS A | Director | Open Market Sale | -1,775 | 9.24 | -16,401.00 | -3,3% | |
| 2025-10-09 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -20,609 | 9.35 | -192,613.77 | -38,6% | |
| 2025-10-08 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -19,605 | 9.47 | -185,722.09 | -37,2% | |
| 2025-10-07 | Southpoint Capital Advisors LP | 10% Owner | Open Market Sale | -26,900 | 9.59 | -257,892.99 | -51,7% | |
| 2025-10-06 | Raykov Rosty | Director | Open Market Sale | -10,000 | 9.78 | -97,800.00 | -19,6% | |
| 2025-09-04 | Raykov Rosty | Director | Open Market Sale | -10,000 | 8.92 | -89,200.00 | -17,9% | |
| 2025-08-05 | Raykov Rosty | Director | Open Market Sale | -10,000 | 8.09 | -80,900.00 | -16,2% | |
| 2025-07-07 | RALLIS CHRIS A | Director | Open Market Sale | -1,119 | 8.71 | -9,746.49 | -2,0% | |
| 2025-07-03 | Raykov Rosty | Director | Open Market Sale | -10,000 | 8.61 | -86,100.00 | -17,3% | |
| 2025-06-05 | Raykov Rosty | Director | Open Market Sale | -10,000 | 7.78 | -77,800.00 | -15,6% | |
| 2025-05-19 | Hackman Jeffrey S. | Director, Officer, Chief Executive Officer | Open Market Purchase | 13,965 | 6.99 | 97,615.35 | +19,6% | |
| 2025-05-16 | Hackman Jeffrey S. | Director, Officer, Chief Executive Officer | Open Market Purchase | 1,035 | 6.75 | 6,986.25 | +1,4% | |
| 2025-05-16 | Raykov Rosty | Director | Open Market Sale | -16,667 | 6.78 | -113,002.26 | -22,6% | |
| 2025-05-05 | Raykov Rosty | Director | Open Market Sale | -10,000 | 6.31 | -63,100.00 | -12,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.